Literature DB >> 1377517

Immune surveillance against Epstein-Barr virus.

D J Moss1, S R Burrows, R Khanna, I S Misko, T B Sculley.   

Abstract

Following primary infection, EBV retains a life-long latent association with B lymphocytes and a permissive association with stratified epithelium in the oropharynx. This review presents a model for the host-virus relationships in healthy virus carriers, a relationship which, if perturbed, may result in EBV-associated disease. Cytotoxic T cells that recognise virally-determined epitopes on infected cells are the major effector arm and control the persistant infection. A strategy for developing a vaccine to EBV is discussed.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1377517

Source DB:  PubMed          Journal:  Semin Immunol        ISSN： 1044-5323            Impact factor:   11.130


  13 in total

1.  Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design.

Authors:  S A Thomson; R Khanna; J Gardner; S R Burrows; B Coupar; D J Moss; A Suhrbier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

2.  Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.

Authors:  S Pepperl; G Benninger-Döring; S Modrow; H Wolf; W Jilg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

Review 3.  The Epstein-Barr virus and its association with human cancers.

Authors:  K R Baumforth; L S Young; K J Flavell; C Constandinou; P G Murray
Journal:  Mol Pathol       Date:  1999-12

4.  Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells.

Authors:  R D Cardin; J W Brooks; S R Sarawar; P C Doherty
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

5.  HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.

Authors:  S P Lee; W A Thomas; R J Murray; F Khanim; S Kaur; L S Young; M Rowe; M Kurilla; A B Rickinson
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  EBV-positive human sera contain antibodies against the EBV BMRF-2 protein.

Authors:  Jianqiao Xiao; Joel M Palefsky; Rossana Herrera; Carl Sunshine; Sharof M Tugizov
Journal:  Virology       Date:  2009-08-20       Impact factor: 3.616

7.  Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus.

Authors:  T A Banks; S Nair; B T Rouse
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

Review 8.  Immune regulation in Epstein-Barr virus-associated diseases.

Authors:  R Khanna; S R Burrows; D J Moss
Journal:  Microbiol Rev       Date:  1995-09

9.  Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.

Authors:  Jiang Li; Qiu-yan Chen; Haoyuan Mo; Yi-lan Zhang; Zhou-feng Huang; Yi-xin Zeng
Journal:  Int J Biol Sci       Date:  2011-05-18       Impact factor: 6.580

10.  An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease.

Authors:  S R Burrows; R Khanna; J M Burrows; D J Moss
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.